SEHK:2696Biotechs
Shanghai Henlius Biotech (SEHK:2696) Reports Strong Half Year Growth, Is It Overvalued?
Shanghai Henlius Biotech (SEHK:2696) drew fresh attention after reporting half year 2026 sales of CNY 3,588.23 million and net income of CNY 430.44 million, alongside a new Hong Kong principal business address.
Shanghai Henlius Biotech’s recent half year update has come alongside a strong shift in market sentiment, with a 22.55% 1 month share price return and a 16.38% year to date share price return, even though the 1 year total shareholder return declined 11.43%.
Spot fresh momentum in...